What is CD4+CD56+ malignancy and how should it be treated?
- 16 September 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 32 (7), 637-646
- https://doi.org/10.1038/sj.bmt.1704215
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique HematologiqueBlood, 2002
- CD56+ TdT+ blastic natural killer cell tumor of the skinCancer, 2002
- Blastic Natural Killer Cell Lymphoma/LeukemiaAmerican Journal of Clinical Pathology, 2002
- CD56+/CD4+ Lymphomas and Leukemias Are Morphologically, Immunophenotypically, Cytogenetically, and Clinically DiverseAmerican Journal of Clinical Pathology, 2001
- Identification of a leukemic counterpart of the plasmacytoid dendritic cellsBlood, 2001
- Blastic NK-cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer-Wright type pseudorosettes formationHistopathology, 1998
- CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous diseaseBritish Journal of Dermatology, 1997
- Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell LymphomasThe American Journal of Surgical Pathology, 1996
- CD2+, CD3‐, CD56/NCAM+ malignant lymphoma with TCRβ gene rearrangement: A case reportAmerican Journal of Hematology, 1995
- Clinicopathologic Study of CD56 (NCAM)-Positive Angiocentric Lymphoma Occurring in Sites Other than the Upper and Lower Respiratory TractThe American Journal of Surgical Pathology, 1995